Editor—As highlighted in a recent edition ofFetal and Neonatal, there is increasing concern about the previously unreported high levels of neonatal group B Streptococcal (GBS) infections in the UK.1 ,2 It is important that we have statistics for regional variations in GBS infection so that we can to produce evidence based guidelines. It is also important that we are clear about the data on which we base our recommendations.

In the commentary which followed our recent paper,2 Nicoll and Heath1 refer to the incidence at which a risk factor based versus a screening approach to the prevention of Group B Streptococcus would be cost effective, quoting from a commentary by Isaacs.3 The original article by Mohle-Boetaniet al from …